VTE Pathophysiology and DOAC Pharmacokinetics in Obesity
 |
VTE Pathophysiology and DOAC Pharmacokinetics in Obesity CME, CPE Daniel M. Witt, PharmD, FCCP, BCPS |
|
| Release Date: March 31, 2022 Expiration Date: March 31, 2023 |
||
|
Join Dr. Witt as he explains how to optimize DOAC pharmacokinetics in patients with obesity. Topics include hemostasis, the impact of obesity on clot formation, and the effects of obesity on DOAC absorption, distribution, metabolism, and excretion. Provided by MediCom Worldwide, Inc.This activity is supported by an educational grant from Janssen Pharmaceuticals, Inc., administered by Janssen Scientific Affairs, LLC. |
||
| View Only, No Credit | ||